The greatest success in metabolic targeting, and a proof of concept that specific modulation of metabolic pathways could result in therapeutic benefit for specific subgroups of AML patients, is differentiative therapy of patients carrying isocitrate dehydrogenase (IDH) mutations with IDH inhibitors. The gene discussed is IDH2; the disease is acute myeloid leukemia.